CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISION] CROSS-LICENSE AGREEMENT This Agreement (the "Agreement") is entered into as of October 14, 2002 (the...Cross-License Agreement • October 3rd, 2006 • MetaMorphix Inc. • Pharmaceutical preparations
CROSS LICENSE AGREEMENT between ASTERIAS and BIOTIME and ESICross-License Agreement • February 22nd, 2016 • Biotime Inc • Biological products, (no disgnostic substances) • Delaware
This CROSS-LICENSE AGREEMENT (the “Agreement”) is entered into on February 16, 2016 (the “Effective Date”) by and between Asterias Biotherapeutics, Inc., a Delaware corporation, having a place of business at 6300 Dumbarton Circle, Fremont, CA 94555 (“Asterias”), BioTime, Inc., a California corporation, having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“BioTime”), and ES Cell International Pte Ltd., a corporation wholly owned by BioTime organized under the laws of Singapore and having a place of business at 1301 Harbor Bay Parkway, Alameda, CA 94502 (“ESI”) (each individually referred to as “Party” and collectively as the “Parties”).
EX-99.3 4 d443535dex993.htm CROSS LICENSING AGREEMENT CROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012 EXHIBIT A – IP MANAGEMENT TERMS 42...Cross-License Agreement • May 5th, 2020 • Delaware
This Cross-License Agreement (this “Agreement”) is entered into as of November 12, 2012 (the “Effective Date”), by and among ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A. (“Alnylam”), TEKMIRA PHARMACEUTICALS CORPORATION, a Canadian corporation having a principal office at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), and, solely with respect to Section 10.12, PROTIVA BIOTHERAPEUTICS INC., a wholly-owned subsidiary of Tekmira and a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”).
INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT BY AND BETWEEN NETGEAR, INC. AND ARLO TECHNOLOGIES, INC. Dated as of August 2, 2018Cross-License Agreement • August 7th, 2018 • Netgear, Inc • Telephone & telegraph apparatus • Delaware
This INTELLECTUAL PROPERTY RIGHTS CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of August 2, 2018, is by and between NETGEAR, Inc., a Delaware corporation, and Arlo Technologies, Inc., a Delaware corporation.
CROSS LICENSE AGREEMENTCross License Agreement • November 13th, 2006 • Hansen Medical Inc • Orthopedic, prosthetic & surgical appliances & supplies • California
This Cross License Agreement (“Cross License”), dated as of September 1, 2005 (“Effective Date”), is made by and between Intuitive Surgical, Inc., a Delaware corporation having its principal place of business at 950 Kifer Road, Sunnyvale, California 94086, (“ISI”), and Hansen Medical, Inc., a Delaware corporation having its principal place of business at 380 North Bernardo Avenue, Mountain View, California 94043 (“Hansen”). Hansen and ISI may be referred to herein individually as a “Party”, and collectively as the “Parties”.
RECITALCross-License Agreement • April 16th, 2001 • Simplex Solutions Inc • Services-computer programming services • California
AMENDED AND RESTATED CROSS-LICENSE AGREEMENT Between ALNYLAM PHARMACEUTICALS, INC. And PROTIVA BIOTHERAPEUTICS INC. Dated: May 30, 2008Cross-License Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Amended and Restated Cross-License Agreement (this “Agreement”) is entered into as of May 30, 2008, by and between ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A., and PROTIVA BIOTHERAPEUTICS INC., a Canadian corporation, having a principal office at 100-3480 Gilmore Way, Burnaby, B.C., Canada.
EX-10.26 32 a2216934zex-10_26.htm EX-10.26 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended....Cross-License Agreement • May 5th, 2020 • Delaware
This CROSS-LICENSE AGREEMENT (this “Agreement”) is made as of December 19, 2012 (the “Effective Date”) by and between MEDIMMUNE, LLC a limited liability company organized under the laws of Delaware, U.S.A., having a principal place of business at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and XENCOR, INC., a corporation organized under the laws of the state of Delaware, U.S.A, having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016, U.S.A. (“Xencor”).
CROSS LICENSE AGREEMENTCross License Agreement • October 31st, 2019 • PF2 SpinCo LLC • Services-computer processing & data preparation
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of March 1, 2017 (the “Closing Date”), is entered into by and among Change Healthcare LLC (f/k/a PF2 NewCo LLC), a Delaware limited liability company (the “NewCo”), eRx Network, LLC, Delaware corporation (“Echo Connect”), and McKesson Corporation, a Delaware Corporation (“MCK”). NewCo, Echo Connect, MCK each may be referred to herein individually as a “Party” and collectively as the “Parties.”
CROSS LICENSE AGREEMENTCross License Agreement • February 4th, 2020 • PF2 SpinCo, Inc. • Services-computer processing & data preparation
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of March 1, 2017 (the “Closing Date”), is entered into by and among Change Healthcare LLC (f/k/a PF2 NewCo LLC), a Delaware limited liability company (the “NewCo”), eRx Network, LLC, Delaware corporation (“Echo Connect”), and McKesson Corporation, a Delaware Corporation (“MCK”). NewCo, Echo Connect, MCK each may be referred to herein individually as a “Party” and collectively as the “Parties.”
FORM OF INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT by and between AIR PRODUCTS AND CHEMICALS, INC. and VERSUM MATERIALS U.S., LLC Dated as ofCross-License Agreement • September 7th, 2016 • Versum Materials, LLC • Miscellaneous chemical products • Delaware
This INTELLECTUAL PROPERTY CROSS LICENSE AGREEMENT (this “Agreement”), dated as of (the “Effective Date”), is entered into by and between Air Products and Chemicals, Inc. (“Air Products”), a Delaware corporation with an address at 7201 Hamilton Boulevard, Allentown, Pennsylvania, 18195, U.S.A., and Versum Materials U.S., LLC (“Versum”), a limited liability company organized under the laws of the State of Delaware with an address at , U.S.A. (both Air Products and Versum, a “Party” and collectively, the “Parties”).
EX-99.3 4 dex993.htm CROSS-LICENSE AGREEMENT B/W PFIZER OVERSEAS PHARMACEUTICALS AND MEDAREX, INC. EXECUTION COPY CROSS-LICENSE AGREEMENTCross-License Agreement • May 5th, 2020
THIS CROSS-LICENSE AGREEMENT (the “Agreement”) is made as of September 15, 2004 (the “Effective Date”) between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017, and its Affiliates (“Pfizer”), and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, New Jersey 08540 (“Medarex”). Pfizer and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
CROSS LICENSE AGREEMENTCross License Agreement • April 28th, 2005 • Imcor Pharmaceutical Co • Pharmaceutical preparations • New York
This CROSS LICENSE AGREEMENT (the “Agreement”) is entered into as of the Effective Date, by and between IMCOR Pharmaceutical Co., a Nevada corporation (“IMCOR”), Bristol-Myers Squibb Company, a Delaware corporation (“BMS”), and Bristol-Myers Squibb Medical Imaging, Inc., a Delaware corporation (together with BMS, referred to herein as “BMSMI”). IMCOR and BMSMI may be referred to separately as a “Party” or collectively as the “Parties”.
CROSS LICENSE AGREEMENTCross License Agreement • January 16th, 2008 • Broncus Technologies Inc/Ca • Surgical & medical instruments & apparatus • California
THIS CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 30, 2003 (the “Effective Date”) by and between Broncus Technologies, Inc., a California corporation having its principal place of business at 1400 N. Shoreline Blvd., Bldg. A, Suite 8, Mountain View, California 94303 (“Broncus”) and Asthmatx, Inc., a California corporation having its principal place of business at 1340 Space Park Way, Mountain View, California 94043 (“Asthmatx”).
AGCO/SPECCO INTELLECTUAL PROPERTY CROSS LICENSE AGREEMENT by and among CORTEVA, INC., AGCO LICENSORS, AGCO LICENSEES, DOWDUPONT INC., SPECCO LICENSORS and SPECCO LICENSEES Dated as of June 1, 2019Cross License Agreement • June 3rd, 2019 • DuPont De Nemours, Inc. • Plastic materials, synth resins & nonvulcan elastomers • Delaware
This AGCO/SPECCO INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of June 1, 2019 (the “Effective Date”), is entered into by and among Corteva, Inc., a Delaware corporation (“AgCo”), the AgCo Licensors and the AgCo Licensees, on the one hand, and DowDuPont Inc., a Delaware corporation (“SpecCo”), the SpecCo Licensors and the SpecCo Licensees, on the other hand (each of AgCo and SpecCo, a “Party” and together, the “Parties”).
CROSS LICENSE AGREEMENTCross License Agreement • August 24th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Cross License Agreement (this “Agreement”) is made as of the Effective Date (as such term is defined below) by and between Asuragen, Inc., a Delaware corporation with its principal offices at 2150 Woodward St., Austin, Texas 78744 (“Asuragen”) and Mirna Therapeutics, Inc., a Delaware corporation with an office at 2150 Woodward Street, Austin, Texas 78744 (“Mirna”); (each of Asuragen and Mirna is referred to herein as “Party” and together as the “Parties”).
MATCO/SPECCO IP CROSS LICENSE AGREEMENTCross License Agreement • April 18th, 2023 • Delaware
This MATCO/SPECCO IP CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of [•] (the “Effective Date”), is entered into by and between DowDuPont Inc. (“SpecCo”), a Delaware corporation, [the SpecCo Licensors and the SpecCo Licensees,] and Dow Holdings Inc., a Delaware corporation (“MatCo”), [the MatCo Licensors and the MatCo Licensees] (each of SpecCo and MatCo, a “Party” and together, the “Parties”).
CROSS LICENSE AGREEMENTCross License Agreement • September 1st, 2011 • Aspen Aerogels Inc • Wholesale-lumber & other construction materials • Massachusetts
Plaintiff Aspen Aerogels, Inc. and defendant Cabot Corporation, constituting all of the parties who have appeared in this proceeding, hereby stipulate, pursuant to Chancery Court Rule 41(a)(1)(ii), that this action, including any and all claims, counterclaims and defenses asserted herein, is hereby dismissed with prejudice and without costs or attorney’s fees to any party.
CROSS-LICENSE AGREEMENTCross-License Agreement • October 1st, 2021 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Cross-License Agreement (“Agreement”), effective as of December 16, 2020 (the “Effective Date”) and executed on February 11, 2021 (the “Execution Date”), is by and among Xilio Development, Inc., a Delaware corporation with an address at 828 Winter Street, Waltham, MA 02451 (“Xilio”), AskGene Pharma, Inc., a Delaware corporation with an address at 5217 Verdugo Way, Suite A, Camarillo, CA 93012 (“AskGene”) and, solely for purposes of Section 12.8, Xilio Therapeutics, Inc., a Delaware corporation with an address at 828 Winter Street, Waltham, MA 02451 (“Parent”). Xilio and AskGene are referred to herein collectively as the “Parties” and each individually as a “Party.”
CROSS-LICENSE AGREEMENT By and Among ALNYLAM PHARMACEUTICALS, INC. TEKMIRA PHARMACEUTICALS CORPORATION And PROTIVA BIOTHERAPEUTICS INC. Dated: November 12, 2012Cross-License Agreement • March 27th, 2013 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Cross-License Agreement (this “Agreement”) is entered into as of November 12, 2012 (the “Effective Date”), by and among ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A. (“Alnylam”), TEKMIRA PHARMACEUTICALS CORPORATION, a Canadian corporation having a principal office at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), and, solely with respect to Section 10.12, PROTIVA BIOTHERAPEUTICS INC., a wholly-owned subsidiary of Tekmira and a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”).
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT by and among BORGWARNER INC. and DELPHI TECHNOLOGIES IP LIMITED and PHINIA TECHNOLOGIES, INC. and BORGWARNER LUXEMBOURG OPERATIONS S.A.R.L. Dated as of June 30, 2023Cross-License Agreement • July 7th, 2023 • Phinia Inc. • Motor vehicle parts & accessories
This INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “IP License Agreement”) dated as of June 30, 2023 (“Effective Date”), is by and among BORGWARNER INC., a Delaware corporation (“Parent”), and DELPHI TECHNOLOGIES IP LIMITED, a Barbados limited company, on the one hand, and PHINIA TECHNOLOGIES, INC., a Delaware corporation, and BORGWARNER LUXEMBOURG OPERATIONS S.À.R.L., a Luxembourg société à responsabilité limitée, on the other hand (collectively, the “Parties,” or each, individually, a “Party”).
CROSS LICENSE AGREEMENTCross License Agreement • October 5th, 2006 • Asthmatx Inc • Surgical & medical instruments & apparatus • California
THIS CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of December 30, 2003 (the “Effective Date”) by and between Broncus Technologies, Inc., a California corporation having its principal place of business at 1400 N. Shoreline Blvd., Bldg. A, Suite 8, Mountain View, California 94303 (“Broncus”) and Asthmatx, Inc., a California corporation having its principal place of business at 1340 Space Park Way, Mountain View, California 94043 (“Asthmatx”).
EX-10.6 13 dex106.htm CROSS LICENSE AGREEMENT CROSS LICENSE AGREEMENTCross License Agreement • May 5th, 2020 • California
This CROSS LICENSE AGREEMENT (this “Agreement”) is made and entered into this 14th day of February, 2011, and effective as of February 1, 2010 (the “Effective Date”), by and between Loyalty Alliance Enterprise Corporation, a company organized and existing under the laws of the Cayman Islands and its Affiliates other than PayEase and its subsidiaries (hereinafter referred to as “LA”), and PayEase Corp., a corporation organized and existing under the laws of the State of Delaware and its Affiliates other than LA and its subsidiaries (“PayEase”). LA and PayEase are referred to herein individually each as a “Party” and collectively as the “Parties”.
Certain confidential information contained in this document, marked by [***], has been omitted because Roivant Sciences Ltd. (the “Company”) has determined that the information (i) is not material and (ii) would likely cause competitive harm to the...Cross License Agreement • December 22nd, 2021 • Roivant Sciences Ltd. • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to the Cross License Agreement dated as of April 11, 2018 by and between Genevant Sciences GmbH, a limited liability company organized and existing under the laws of Switzerland (“Company”), a Subsidiary of Genevant Sciences Ltd. (“Genevant”), as assignee of Genevant, and Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus”), as previously amended by two separate amendments each dated as of June 27, 2018 (the “Agreement”), is entered into and made effective as of the date of signature of the later of Company and Arbutus to sign below (the “Third Amendment Effective Date”). Arbutus and Company are sometimes referred to in this Amendment collectively as the “Parties” and individually as a “Party.” Capitalized terms used but not otherwise defined herein have the respective meanings ascribed to such terms in the Agreement.
CROSS LICENSE AGREEMENTCross License Agreement • March 6th, 2012 • Endologix Inc /De/ • Surgical & medical instruments & apparatus • New Jersey
This CROSS LICENSE AGREEMENT (this “Agreement”) is made effective as of the 26th day of October, 2011 (“Effective Date”), by and between Bard Peripheral Vascular, Inc., an Arizona corporation, with an address at 1415 W. Third Street, Tempe AZ 85281 (“Bard”), and Endologix, Inc., a Delaware corporation, having a principal place of business at 11 Studebaker Irvine, California 92618 (“Endologix”). Bard and Endologix are, collectively, referred to herein as the “Parties,” or, individually, as a “Party.”
CROSS LICENSE AGREEMENTCross License Agreement • August 27th, 2020 • Maxeon Solar Technologies, Ltd. • Semiconductors & related devices
This CROSS LICENSE AGREEMENT (the “Agreement”) has been entered into as of August 26, 2020 (the “Effective Date”) by and between SunPower Corporation (“SPWR”), a Delaware corporation, and Maxeon Solar Pte. Ltd. (“MSSG”), a Singapore corporation. SPWR and MSSG may also be referred to individually as a “Party” or collectively as “Parties.”
CROSS LICENSE AGREEMENT DATED AS OF MARCH 21, 2007 (“AGREEMENT”) BETWEEN APPLICA INCORPORATED (“APPLICA”) AND SALTON, INC. (“SALTON”) BackgroundCross License Agreement • June 28th, 2007 • Salton Inc • Electric housewares & fans • New York
A Applica owns or has the right to use and license certain intellectual property related to the marketing, distribution and sale of portable household appliances.
CROSS LICENSE AGREEMENTCross License Agreement • December 29th, 2006 • Sensata Technologies Holland, B.V. • New York
This CROSS LICENSE AGREEMENT (this “Agreement”), dated as of April , 2006 (the “Effective Date”), is entered into by and between Texas Instruments Incorporated, a Delaware corporation (“Seller”), and Sensata Technologies B.V., a Dutch limited liability company, formerly known as Potazia Holding B.V., assignee of S&C Purchase Corp. (“Buyer”) (each a “Party” and collectively, the “Parties”).
CROSS LICENSE AGREEMENT by and between ALIBABA GROUP HOLDING LIMITED and (ANT SMALL AND MICRO FINANCIAL SERVICES GROUP CO., LTD.) Dated as of September 23, 2019Cross License Agreement • November 13th, 2019 • Alibaba Group Holding LTD • Services-business services, nec • New York
This CROSS LICENSE AGREEMENT (the “Agreement”), dated as of September 23, 2019 (the “Effective Date”), is made by and between the following parties (each of which shall be referred to individually as a “Party” and which are referred to collectively as the “Parties”):
Amended and Restated Cross-License AgreementCross-License Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Cross-License Agreement (the “Agreement”) is entered into as of June 28, 2004 (the “Amendment Date”) and is hereby made effective as of April 9, 2002 (the “Effective Date”), by and between Micromet AG, having its principal offices at Staffelseestrasse 2, 81477 Munich, Germany (“Micromet”), and Enzon Pharmaceuticals, Inc., having its principal offices at 685 Route 202/206, Bridgewater, New Jersey 08807, USA (“Enzon”). Micromet and Enzon each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CROSS-LICENSE AGREEMENTCross-License Agreement • April 7th, 2003 • Michigan
This Cross License Agreement (“Agreement”), effective as of the date of the signature of the last party to sign below, made by and between United State Automotive Materials Partnership, a Michigan partnership formed with DaimlerChrysler Corporation, Ford Motor Company and General Motors Corporation as its partners, having a business address at C/O USCAR, Suite 300, 1000 Town Center Building; Southfield, MI 48075 (hereinafter, “USAMP”), and
Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would cause competitive harm to Arbutus Biopharma Corporation if publicly disclosed. CROSS LICENSE AGREEMENT by and between GENEVANT SCIENCES...Cross License Agreement • August 7th, 2020 • Arbutus Biopharma Corp • Pharmaceutical preparations • New York
This CROSS LICENSE AGREEMENT (this “Agreement”) is entered into as of April 11, 2018 (the “Effective Date”), by and between Genevant Sciences Ltd., a Bermuda exempted limited company (the “Company”), and Arbutus Biopharma Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Arbutus”). Capitalized terms when used in this Agreement have the meanings set forth in Article I.
CROSS-LICENSE AGREEMENTCross-License Agreement • October 29th, 2007 • Emphasys Medical, Inc. • Surgical & medical instruments & apparatus • Delaware
This cross-license agreement is effective this 21st day of January, 2005 (“Effective Date”), by and between SPIRATION, Inc., a Delaware corporation with principal offices in Redmond, Washington, (hereinafter “Spiration”), and EMPHASYS MEDICAL, INC., a Delaware corporation with principal offices in Redwood City, California (hereinafter “Emphasys”).
Exhibit 2.2 CROSS-LICENSE AGREEMENT This CROSS-LICENSE AGREEMENT, dated as of May 17, 1999 (the "Cross License Agreement"), is by and among BioSepra Inc., a Delaware corporation ("BioSepra") and its successors or assigns, Life Technologies, Inc., a...Cross-License Agreement • August 2nd, 1999 • Biosphere Medical Inc • Miscellaneous chemical products • Delaware
THIRD AMENDMENT TO CROSS LICENSE AGREEMENTCross License Agreement • December 10th, 2021 • Arbutus Biopharma Corp • Pharmaceutical preparations
This Third Amendment (this “Amendment”) to the Cross License Agreement dated as of April 11, 2018 by and between Genevant Sciences GmbH, a limited liability company organized and existing under the laws of Switzerland (“Company”), a Subsidiary of Genevant Sciences Ltd. (“Genevant”), as assignee of Genevant, and Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus”), as previously amended by two separate amendments each dated as of June 27, 2018 (the “Agreement”), is entered into and made effective as of the date of signature of the later of Company and Arbutus to sign below (the “Third Amendment Effective Date”). Arbutus and Company are sometimes referred to in this Amendment collectively as the “Parties” and individually as a “Party.” Capitalized terms used but not otherwise defined herein have the respective meanings ascribed to such terms in the Agreement.
